Sanofi to outsource antiinfectives R&D to Evotec
Evotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofi’s antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agreement.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Experts forecast the industry’s biggest developments at Pharmapack Europe
Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018.
Heidelberg Pharma inks US$334m R&D contract with Magenta Therapeutics
Under an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes for bone marrow transplants.
Investors keen to put money into AMR SMEs
Investments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus on innovations developed by SMEs, were presented to 200+ AMR stakeholders.
Santhera’s idebenone not efficient in PPMS patients
Swiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval in Duchenne muscular dystrophy last September, an NIH-sponsored trail now showed no difference to placebo treatment in patients with primary progressive multiple sclerosis (PPMS).
Inhaled IL-4 halts neuron destruction in MS models
An US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system.
Convert Pharmaceuticals SA closes €13.6m Series A round
Liège-based Convert Pharmaceuticals SA has been granted a total of €13.6m in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive support by the Walloon region and funds from the European Eurostars programme.
Novo Holdings launches €135m fund to combat antimicrobial resistance
Novo Holdings has launched the REPAIR impact fund commissioned by the Novo Nordisk Foundation. The goal is to invest into early-stage drug developers with new concepts to fight antimicrobial resistance (AMR).
Bavarian Nordic and AZ combine cancer jab with durvalumab
AstraZeneca (AZ) and Bavarian Nordic (BN) combine BN’s cancer vaccine CV301 and AZ’s PD-L1 checkpoint blocker durvalumab in an investigator-sponsored trail to check synergistic effects in patients with colorectal and pancreatic cancer overexpressing CEA and MUC-1.
EMA recommends two orphan drugs for approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting.